Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−48.13 M EUR
173.23 K EUR
62.81 M
About InflaRx N.V.
Sector
Industry
CEO
Niels Christoph Riedemann
Website
Headquarters
Jena
Founded
2007
ISIN
NL0012661870
FIGI
BBG00NZJHSP2
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IF0 is 1.18 EUR — it has increased by 7.66% in the past 24 hours. Watch InflaRx N.V. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange InflaRx N.V. stocks are traded under the ticker IF0.
IF0 stock has risen by 7.37% compared to the previous week, the month change is a 14.24% rise, over the last year InflaRx N.V. has showed a −15.15% decrease.
We've gathered analysts' opinions on InflaRx N.V. future price: according to them, IF0 price has a max estimate of 8.60 EUR and a min estimate of 1.72 EUR. Watch IF0 chart and read a more detailed InflaRx N.V. stock forecast: see what analysts think of InflaRx N.V. and suggest that you do with its stocks.
IF0 stock is 3.51% volatile and has beta coefficient of 0.70. Track InflaRx N.V. stock price on the chart and check out the list of the most volatile stocks — is InflaRx N.V. there?
Today InflaRx N.V. has the market capitalization of 78.43 M, it has decreased by −20.28% over the last week.
Yes, you can track InflaRx N.V. financials in yearly and quarterly reports right on TradingView.
InflaRx N.V. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
IF0 earnings for the last quarter are −0.21 EUR per share, whereas the estimation was −0.21 EUR resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.15 EUR per share. See more details about InflaRx N.V. earnings.
InflaRx N.V. revenue for the last quarter amounts to 39.43 K EUR, despite the estimated figure of 39.43 K EUR. In the next quarter, revenue is expected to reach 69.14 K EUR.
IF0 net income for the last quarter is −13.88 M EUR, while the quarter before that showed −8.09 M EUR of net income which accounts for −71.63% change. Track more InflaRx N.V. financial stats to get the full picture.
No, IF0 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 30, 2025, the company has 74 employees. See our rating of the largest employees — is InflaRx N.V. on this list?
Like other stocks, IF0 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade InflaRx N.V. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So InflaRx N.V. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating InflaRx N.V. stock shows the sell signal. See more of InflaRx N.V. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.